1). Although attention has historically focused on Grb2-mediated recruitment to receptor tyrosine kinases as a means of localizing SOS to the plasma membrane, recent work has revealed increasing ...

Recent Pre-Clinical Studies Showed BP1001-A Attenuated Fatty Acid-Induced Insulin Resistance and Restored Insulin Sensitivity in Muscle Progenitor and Skeletal Muscle Fiber Cell Models HOUSTON, March ...

By targeting Grb2, the treatment demonstrated potential in lowering blood glucose levels. This approach is seen as a promising alternative to current weight loss drugs that struggle to show ...

Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers, and BP1001-A, a drug product modification of prexigebersen ...

Bio-Path is a biotechnology company developing DNAbilize ®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous infusion.